Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating

With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the 10 Most Undervalued Value Stocks to Buy Now.

Citi Raises PT on Pfizer Inc. (PFE) to $26; Maintains ‘Neutral’ Rating

A closeup shot of a laboratory technician handling a medical device used for fertility treatments.

Following the company’s strong Q2 performance, Citi raised its price target on Pfizer Inc. (NYSE:PFE) from $25 to $26 on August 6, 2025, maintaining a ‘Neutral’ rating. The analyst attributed the target revision to strong results. At the same time, Citi advised caution regarding continued policy uncertainties.

Pfizer Inc. (NYSE:PFE) reported 10% revenue growth, taking total revenue to $14.7 billion. The top-line growth was driven by strong sales of the Vyndaqel product family, Comirnaty, Paxlovid, Padcev, Eliquis, and other products. At the quarter-end, the company also reiterated its 2025 revenue guidance of $61.0-$64.0 billion, while raising its adjusted diluted EPS outlook by $0.10 at the midpoint to $2.90-$3.10. This guidance raise was made despite challenges caused by the Inflation Reduction Act’s Medicare Part D redesign.

Pfizer Inc. (NYSE:PFE) discovers, develops, and markets biopharmaceutical products globally. It is included in our list of the most undervalued value stocks to buy.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.